- Home
- VEEA vs SLS Comparison
VEEA vs SLS Comparison
Compare VEEA & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEA
- SLS
- Stock Information
- Founded
- VEEA 2014
- SLS 2012
- Country
- VEEA United States
- SLS United States
- Employees
- VEEA N/A
- SLS N/A
- Industry
- VEEA
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- VEEA
- SLS Health Care
- Exchange
- VEEA NYSE
- SLS Nasdaq
- Market Cap
- VEEA 84.8M
- SLS 75.3M
- IPO Year
- VEEA N/A
- SLS N/A
- Fundamental
- Price
- VEEA $2.52
- SLS $1.17
- Analyst Decision
- VEEA
- SLS Buy
- Analyst Count
- VEEA 0
- SLS 1
- Target Price
- VEEA N/A
- SLS $3.00
- AVG Volume (30 Days)
- VEEA 394.2K
- SLS 797.4K
- Earning Date
- VEEA 11-20-2024
- SLS 11-13-2024
- Dividend Yield
- VEEA N/A
- SLS N/A
- EPS Growth
- VEEA N/A
- SLS N/A
- EPS
- VEEA N/A
- SLS N/A
- Revenue
- VEEA $140,035.00
- SLS N/A
- Revenue This Year
- VEEA N/A
- SLS N/A
- Revenue Next Year
- VEEA N/A
- SLS N/A
- P/E Ratio
- VEEA N/A
- SLS N/A
- Revenue Growth
- VEEA N/A
- SLS N/A
- 52 Week Low
- VEEA $2.14
- SLS $0.50
- 52 Week High
- VEEA $18.56
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- VEEA N/A
- SLS 42.81
- Support Level
- VEEA N/A
- SLS $1.22
- Resistance Level
- VEEA N/A
- SLS $1.39
- Average True Range (ATR)
- VEEA 0.00
- SLS 0.10
- MACD
- VEEA 0.00
- SLS -0.00
- Stochastic Oscillator
- VEEA 0.00
- SLS 12.00
About VEEA VEEA INC
Veea Inc is a company providing edge platform having extensive knowledge and expertise on content delivery and edge computing, and has brought a broad range of Wi-Fi, 4G/5G mobile wireless, and IoT products to market over the past two decades. It has first-in-class VeeaHub smart computing hubs integrate a full range of connectivity options, application processing power, and a full security stack to form an elastic edge computing platform with a dynamic connectivity and application mesh that can easily be deployed and centrally managed from the cloud.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.